Trial
NCT03382899
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
ARMO BioSciences
Condition
Non Small Cell Lung Cancer
Intervention
Pegilodecakin
Why stopped
The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit ratio is unfavorable.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-20